Monthly Archives: January 2024

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.

Read More

Genprex Provides Business Update and Outlook for 2024 

Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024

Poised for FDA guidance regarding diabetes gene therapy program in 2024

Read More